The Hepatitis B Foundation and its Baruch S. Blumberg Institute are the nation’s leading nonprofit disease advocacy and research organizations dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. The Hepatitis B Foundation was founded in 1991 and established the Blumberg Institute in 2003 to fulfill its research mission.

FOR NEARLY THREE DECADES, the Hepatitis B Foundation and our research arm, the Baruch S. Blumberg Institute, have been leading the charge to bring hepatitis B outreach, research and advocacy to the forefront. We have adopted a bold strategy to give a louder voice to this silent epidemic—brining it into the spotlight to elevate awareness, increase vaccination, screening and linkage to care, accelerate research, and ultimately cure this deadly disease.

Our five-year strategic plan, approved in 2018, is rooted in an aggressive vision:

BY 2030, NO ONE DIES FROM HEPATITIS B.

WE ARE CONFIDENT THAT A CURE FOR HEPATITIS B IS WITHIN OUR REACH, and we are recruiting the best scientists in the field to encourage collaboration, share their progress, and bring a cure to market. We recognize, however, that a cure alone is not enough for our vision. Our plan also includes continuing and expanding our existing programs to emphasize prevention, and provide critical assistance for those managing the disease. Through our Hep B United program, we have set the standard for building coalitions within at-risk communities to provide free awareness, testing, and linkage to care. We have implemented a ground-breaking global initiative in Haimen City, China, that will act as a model as we expand into other highly-affected regions of the world. And we continue to provide information and guidance directly to thousands of people who contact us for help each year. Your commitment to our mission has made all these programs possible, and your continued support will bring us even closer to our vision of a world where hepatitis B is no longer deadly.

Fifty years after its discovery, hepatitis B is still the most common liver disease in the world. It thrives in silence, but our voices together can make hepatitis B history. We have a clear plan in place to lead hepatitis B into the forefront of scientific advances and public health planning, and eliminate deaths from this virus within our lifetimes. Your continued support has made these advances possible.
Through our research arm, the Baruch S. Blumberg Institute, we are relentlessly researching promising new innovative treatments for liver cancer and a cure for hepatitis B. Nearly 50 scientists work at our Blumberg Institute—one of the largest nonprofit groups of researchers investigating hepatitis B, liver cancer, and other liver diseases in the world. Our work extends beyond our own laboratories, to the larger hepatitis B research community. In 2018, our Roadmap to a Cure was published in *Hepatology*, providing a consensus statement from leading researchers to identify the most promising areas of focus for hepatitis B and liver cancer science, and approaches considered necessary for a cure.

**We expect more of our discoveries, and discoveries that we inspire, to reach human trials soon. Our successes from the past year are highlighted in this report.**

### Advancing Hepatitis B and Liver Cancer Research

**Reaching clinical trials**

4 of our promising findings moved into clinical trials in 2018, including two for hepatitis B treatment, one for cancer treatment and one for cancer detection.

**Reaching the scientific community**

Our Scientists published 40 peer-reviewed publications in leading research journals.

Keeping a focus on drug discovery and the basic science of disease, we have:

- Identified compounds with novel activity against HBsAg
- Identified new biomarker to detect liver cirrhosis and liver cancers
- Identified a novel compound, KPD10, through our cell-based high-throughput compound screening, which selectively kills HCC cells expressing HBV surface antigen
- Found method of selective killing of hepatocellular carcinoma cells by exploiting HBV surface antigen expressed on HCC cells
- For use as a new, non-invasive marker of HCC, identified HBV sequences integrated adjacent to cell oncogenes from the urine of people with HCC
- Identified cellular proteins that HBV needs to produce cccDNA and to repress cccDNA expression
- Discovered HBV’s unusual process of producing its “mRNA”
- Found STING agonist as therapeutics for cancers and chronic viral infectious diseases
- Identified and characterized antiviral drug candidate against yellow fever virus, with a new mechanism of action

See hep.org/research for more information on our research accomplishments.
More than 500 hepatitis B and liver cancer scientists attended the 2018 International HBV Meeting in Taormina, Italy, coordinated by HBF.

We hosted 30 seminars by scientific leaders at Baruch S. Blumberg Institute.

BRINGING LEADERS TOGETHER

We provided expert presentations at over 25 national and international conferences.

TRAINING THE RESEARCHERS OF TOMORROW

7 Post doctoral Fellows
from universities worldwide

18 Graduate Students
from Drexel University, Geisinger Commonwealth School of Medicine and The University of Pennsylvania trained at Blumberg Institute

6 Medical Students
from Xavier Medical School conducted research rotations at Blumberg

3 Junior Research Fellows
joined our labs to prepare themselves for careers in science and business

7 Undergraduate College Students
from Drexel, Cornell, Temple, Penn State conducted research in our labs

25 High School Students
trained through our new educational programs this year as part of our commitment to tomorrow’s scientists. An exciting new collaboration with Central Bucks School District brought 15 advanced placement chemistry students to the Blumberg Institute every day to conduct real-world research in our labs. Another 10 high school students participated in our celebrated summer program.
HEPATITIS B CAN BE an overwhelming and confusing diagnosis. Our trained staff answer questions about test results, transmission, vaccinations, and care, and help patients to understand what their diagnosis means for their health and their future. We guide people with hepatitis B as they face their diagnosis, and provide guidance for telling loved ones, finding care, and starting a family.

This year, we educated patients, family members, employers and health officials through:

- **9,953** consultations via phone, email, and social media
- **1.8 million** visits to our website, representing over 200 countries
- **12** Updated website chapters in 12 languages

In 2018, we started collecting caller data from phone consults.

<table>
<thead>
<tr>
<th>Query</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>test results</td>
<td>35%</td>
</tr>
<tr>
<td>vaccine info</td>
<td>30%</td>
</tr>
<tr>
<td>transmission</td>
<td>17%</td>
</tr>
<tr>
<td>finding a doctor</td>
<td>11%</td>
</tr>
<tr>
<td>newly diagnosed</td>
<td>10%</td>
</tr>
<tr>
<td>possible exposure</td>
<td>10%</td>
</tr>
</tbody>
</table>

NATIONAL STORYTELLING CAMPAIGN SHINES A SPOTLIGHT ON HEPATITIS B

There is no better way to raise public understanding about the true impact of hepatitis B than through personal stories. In 2017, the Hepatitis B Foundation unveiled its #justB national storytelling campaign with real people sharing their stories about hepatitis B. This national storybank is designed to put a human face on hepatitis B in order to increase public awareness, decrease stigma and discrimination, and to promote testing and treatment, which will ultimately save lives.

Forty storytellers share their experiences with hepatitis B and liver cancer both online, and at in-person educational events throughout the U.S. Over 2.2 million people have viewed our stories, improving awareness around the world. 

You can watch all our #justB stories at [www.hepb.org/justb](http://www.hepb.org/justb).

CONNECTING PATIENTS WITH OUR PROGRAMS

In addition to hepatitis B outreach, we also offer programs to provide support and information for conditions that impact people with hepatitis B:

**Hepatitis Delta Connect** aims to increase awareness and education about this deadliest form of viral hepatitis, which only infects those with hepatitis B. Information is available in 3 languages, and we have connected with 500 individuals for consults, and reached 3,000 people through our educational webinars. Visit [www.hepDconnect.org](http://www.hepDconnect.org).

**Liver Cancer Connect** works to educate those at risk for liver cancer and provides support through its email helpline and social media channels for patients and families. Visit [www.livercancerconnect.org](http://www.livercancerconnect.org).
TO REACH OUR GOAL of reducing deaths from hepatitis B, the Hepatitis B Foundation issued a formal recommendation this year that all Americans be tested for hepatitis B. To bring the disease to the forefront, we must be aggressive in our efforts to test, vaccinate, treat, and prevent the spread of hepatitis B. But we can’t stop there. We will continue to build new coalitions, and support existing efforts to ensure that every infected person knows their status and has access to care that can save their life.

HEP B UNITED

Hep B United, a national coalition established by HBF in partnership with the Association of Asian Pacific Community Health Organizations, has demonstrated great success in bringing community leaders, providers, medical and public health students, and state and local health departments together with at-risk communities. Hep B United added 4 new partners this year bringing our reach to 30 cities in 21 states.

Hep B United brought over 80 of our coalition partners together for its 6th Annual National Summit to advance our movement to address and eliminate hepatitis B. The Hepatitis B Foundation also facilitates our local coalition, Hep B United Philadelphia (HBUP), which serves a vital role as a mentor for newly-formed coalitions in other cities, and as a testing ground for new programs.

In 2018, Hep B United Philadelphia educated over 2,000 people, screened 150, and linked 90% of infected individuals to care. We also hosted professional trainings for over 150 clinicians and public health partners.

Increasing awareness, screening, vaccination and linkage to care

- 21 States
- 30 Cities

Hep B United
hepbunited.org
Hep B United Summit brought over 80 of our hepatitis B coalition partners together for HBU’s 6th Annual Summit to advance our movement to address and eliminate hepatitis B.

COALITION AGAINST HEPATITIS IN PEOPLE OF AFRICAN ORIGIN

HBF leads the national Coalition Against Hepatitis in People of African Origin (CHIPO), a community coalition of organizations to address the high rates of hepatitis B infection among African communities in the U.S. This year, our work included a collaboration with the Centers for Disease Control and Prevention (CDC) to create a broad scale educational initiative to promote hepatitis B awareness and testing for African immigrants across the United States. This exciting project is the first of its kind to provide targeted educational materials to often-overlooked African immigrant communities.

INTERNATIONAL REACH

Since 2011, the Hepatitis B Foundation has sponsored an ambitious public health campaign in Haimen City, China to reach all 1 million residents with information about hepatitis B. Building on our success in China, we have partnered with organizations to help them bring hepatitis B awareness, testing and care in Ho-Chi Minh, Vietnam and Accra, Ghana.
THROUGH OUR EFFORTS, the hepatitis B voice has grown steadily louder in Washington, DC. As the recognized authority on the fight against hepatitis B, The Hepatitis B Foundation has led the charge to bring government attention and funding to the epidemic of viral hepatitis. We have also worked to fight persistent discrimination that people with hepatitis B face as they apply to work, go to school, enlist in the military, and seek healthcare.
HEP B CURE CAMPAIGN

Hepatitis B has long been underfunded in contrast to government spending on similar epidemics. The Hepatitis B Foundation has focused our efforts on a major advocacy campaign, the Hep B Cure Campaign, aimed to double federal spending on hepatitis B. Our Cure Campaign has already seen success with publication of our Roadmap for a Cure, which identifies areas of promising research and funding. We are working to continue our efforts to increase funding for research by $39 million a year for the next six years, and are advocating for better coordination of research through the National Institutes of Health.

HEP B UNITED ADVOCACY DAY BRING THE MESSAGE TO WASHINGTON

During the Hep B United Advocacy Day, nearly 70 advocates met with more than 60 Congressional offices to discuss increasing federal resources to address and eliminate hepatitis B and liver cancer. We also now reach over 430 people through our online grassroots advocacy network, at hepunited.org.

FIGHTING DISCRIMINATION IN THE U.S.

The Hepatitis B Foundation is working tirelessly to end the stigma and ensure that people with hepatitis B are afforded the same opportunities as everyone else. Our advocacy successfully made hepatitis B a protected condition under the Americans with Disabilities Act (ADA) in the United States, and we continue to fight to ensure that people receive those protections. In addition to ensuring that medical schools and employers comply with ADA protections, we are also fighting for fair access to medicines. Learn more about our work at hep.org/rights.
THE HEPATITIS B FOUNDATION IS committed to a future without hepatitis B, and we have a plan to get there. In 2018, we adopted an ambitious five-year plan based around the vision that by 2030, no one dies of hepatitis B. Our Roadmap to Cure provides a blueprint for the research necessary to bring better treatments and a cure, and our public health priorities support the education, awareness and infrastructure needed to stop the spread of the virus.

ACHIEVING OUR VISION WILL REQUIRE A GLOBAL FOCUS TO EXPAND OUR RESOURCES AND CAPABILITIES ACROSS THE WORLD IN ORDER TO »
Create a Patient Voice

Our presence in communities of high prevalence must increase. Education, awareness, and advocacy on behalf of individuals fighting discrimination and stigma is underway, but we know there are many more cases of people suffering from workplace, military, and educational access discrimination. Working with our coalition of partners across the country, we can help them scale up efforts in over 20 states.

Improve International Capacity

Internationally, resources are scattered and uncoordinated. But the Hepatitis B Foundation is poised, as the global leader in this space, to take on the challenge and build an international coalition similar to the United States Hep B United model, resulting in “Hep B United Global” or “HBUG”. This will lay the groundwork for projects in 5 different countries around the globe to save millions of lives.

Foster discovery of a cure for hepatitis B

We need to give the scientists of the Baruch S. Blumberg Institute the tools to conduct cutting edge research. Vision, commitment and patience is required to accelerate the pace toward a “functional” cure, which we believe exists somewhere within the new wave of HBV therapeutics.
The Hepatitis B Foundation's valuable research and programs are made possible by the commitment of our donors. We are grateful to every individual and organization that has generously supported our mission to find a cure and improve the quality of life for those affected by hepatitis B.

Our Donor Honor Roll

**JANUARY - DECEMBER 2018**

**VISIONARY CIRCLE**
($10,000 AND ABOVE)
Anonymous
Arbutus Biopharma
Timothy & Joan M. Block
Carol and Edmund Blake Foundation
Dynavax
Eiger Biopharmaceuticals, Inc.
Fred Beans Family of Dealerships
Gilead Sciences, Inc.
Kahn Charitable Foundation, Shannon Wu & Joseph Kahn
Prevent Cancer Foundation
Quest Diagnostics
RFS Family Foundation, Raymond Schinazi
Roche-Genetech
Spring Bank Pharma
Univest Corporation of PA
Catharine & Rob Williams

**GLOBAL CIRCLE**
($5,000 TO $9,999)
Alnylam US, Inc.
Arrowhead Pharmaceuticals Inc.
Assembly Biosciences, Inc.
Bristol-Myers Squibb
Alan & Patty Brownstein
CTC Foundation
Linda London
Merck & Co.
Penn Community Bank
Softerware Inc.
Priscilla Tenen
Paula Wong & W. Robert Magee, Jr.

**FOUNDER’S CIRCLE**
($2,500 TO $4,999)
Nathaniel Brown
Bonnie Chang & Robert Hsu
EisnerAmper LLP
Anthony & Jane Ford-Hutchinson
Herman Goldman Foundation
High Swartz LLP
KMT Hepatech Inc.
Faye & Mayer Krupp Family Charitable Foundation
Lion TCR
Bruce & Cynthia Maryanoff
Norwood Company
Joel Rosen
Worldwide Life Sciences

**PRESIDENT’S CLUB**
($1,000 TO $2,499)
Abbott Laboratories
ADMA Biologics, Inc.
Jon Biedermann
Blank Rome LLP
Stanley & Gerri Broadbent
Carol Brosgart
Bob & Joyce Byers
Richard & Flo Celender
Gang Chen
M bn Chen
Char & Paul Cohen
Steve & Janet Cohen
Thomas Shenk & Lillian Chiang
Molli & Joe Conti
David Family Charitable Foundation
Craig & Janet Esterly
Fisher Scientific
Fulton Bank Premier Division

Geisinger Commonwealth School of Medicine
Gilmore & Associates Inc.
Glycostem
Adam Grossman
David & Cynthia Gruber
Anne Heacock
Ram Kapur
Kevin Kruse
Lafayette Ambassador Bank
Patrick Lam
Arthur & Nancy Laskin
James Laskin
Limbach Co. LLC
Mary Anne McDonald & Joseph Benning
Richard Moyer
Network for Good
Anna O’Connell
Timothy Ocain
OrthogenRx, Inc.

Penn Color, Inc.
Yusheng Qu
Richman Chemical Inc.
Spark Nonprofit Consulting LLC
Stark & Stark
Tulchin Family Foundation
Nagachaitanya Velanki
Michael Wehner
Wojdak Government Relations
Worth & Company, Inc.
Wayne Yetter
Tianlun & Amy Zhou
PATRONS ($500 TO $999)
Matthew & Wendy Adlai-gail
Anonymous
Clement Au
Eileen Beck
Bee Bergvall & Co.
Terri Chen
Conifer Point Pharmaceuticals
CP Commercial Printing
William Delaney
Demuzs Brothers, Inc.
Donation Line, LLC
Yaming Du
Greene Street Pharmaceuticals
Maureen Kamischke
Louis & Jeannie Kassa
Kathleen Kerrigan
Anna Lee
Lewis and Rosebud Roberts Family Fund
Madison Associates, LLC
Michele Nasti
Debora Nelson
Rasna Therapeutics
Lewis Roberts
Samuel P. Mandell Foundation
Daniel and Lena Solaiman
Michael & Charleen Sofia
Leaf Sternberg
Lishan Su
Ying Hsu Su & Wei Song
Tiziana Life Sciences
Jean Vdoni
A. Rhodes Wilson
Paul & Jan Witte

FELLOWS ($250 TO $499)
Leo Adalbert
Ark Pharm
Blooming Minds Design, LLC
Gregory and Susan Braithwaite
Anthony Cha
Daniel Chan
Jinhong Chang
Joly Chang
Feng Chen
Del Val Power and Light, Inc.
Sejong Ding
John Ellis
Karl Emerson
Brian C Eves, Esq.
Lalo Flores
Daniel & Jamie Fox
Fox Chase Chemical Diversity Center
Alan Freedman
Anne Frey
Frontier Scientific
Roger & Nancy Gallic
Graphic Edge, Inc.
Richard Grillo
Ronyi Gu
Ju-Tao Guo
He-Won Hann
Franklin & Carol Hart
Virginia Heatwole
Jean Holmes & Lisa Mathson
Eva Honsa-Hogg
Immunorestitution, Inc.
InterLink Biotechnologies
IteraMed Consulting LLC
JBS Science, Inc.
Joanne Jensen
Margaret Keenan
Robert Kelley
Peter Lamberts
Jennifer Maher
Brian McMahon
Lougan Mourad
Moyer Indoor Outdoor
PNC Wealth Management
Kenneth & Maria Rothstein
Guiseppe Sarrica
Caroline Satchell
Christoph & Mirjam Seeger
Susan Stellini
Tescom, Inc.
Walter Tsou
Dennis Wen
Woodmansee & Co.
George and Cathleen Woods
Anchi Wu
Mary Yee
Cheng Zeng

SUPPORTERS ($100 TO $249)
Ishola Adeyemo
Ovidiu Aldea
Laurie & James Beckert
Susan Belaire & John Massey
Sandra Bentd
Joanne Blasenham
Jennifer Boardman
Bill & Mary Kell Cayley
Everett & Diana Chambers
Garrett Chang
Cong Cheng
David & Kathleen Christenson
Margaret Copeland
Andy Cuconati
Zebene Deresse
Mary Cushing Doherty
William Donaldson
Mike Dugery
Exude, Inc.
Theodore Feldstein
Kurt & Janet Ferguson
Edward Fischer
KT Foundation
Brian Free
Lawrence Friedman &
Mary Jo Cappuccilli
Curt & Rosanne Friehs
Edan Gal
Michelle Gerber
Joseph Gonnella
William Green
Hunt Hawkins & Elaine Smith
David Hines
Peter Hoekstra
Max Holt
Kenny Horn
Yuko Huang
Julie Jacob
Jeffrey Jacobson
Amy Jessop
Donald & Kimberly Jungkind
Karen Lassman-Eul
Peter Leone
Edward Lin
Michael Line
Amy Liu
Dapeng Liu
Jessica Lorenz
Kenneth Lu
Emily Mao McCarty
Jennifer Miller
James & Barbara Mongold
Catherine Morris &
Richard Bader
Markus Musa
Meredith Nash
Deigo Mora Navarro
Richard & Teresa O’Flynn
John Oldani
Anthony Oppenheim &
Cathy Block
Val Orekhov
Linda Park
Steve Pelland
Janet Perper
Rupali Praveen
Paul Raetsch
James & Kathleen Ryan
Jasmin Sabado
Ronald & Joyce Sanderson
Y. Clement Shiek
Toby Sherwood
Jim & Kathleen Shryock
Thomas & Harriet Stenzel
Sterotherapeutics, LLC
Linhui Sui
David Sul
Susan Sun
James Talamonti
Judy Tam
Gary Triorzi
Philip & Philippa Wharton
Roy Williams
Sharil & Steve Winkler
Stephen Wong
Onanong Wongwichai
Kechang Wu & Yuling Lo
Yalin Xiong
Shihyun You
Mariissa Yu
Thomas Zipp

FRIENDS (UP TO $99)
Joann Albert & Daniel Green
V. Alexiades
Kyle Anderson
Priyanka Banerjee
Patricia Benham
Janet Bergstrom
Kamlesh Bhagnani
Steven Bingham & Jack Leonard
Steve Black
Geraldine Block
Ron & Debbie Blough
Stephen Borowski
Elaine Brennan
Robert Brit
Nelson Campbell
Paolo Cecchetti
Ka-Ming Chan
Recognizing donors who have included HBF in their wills or made a planned gift

Timothy and Joan Block
Craig and Janet Estery
Jean Miller
C. Theodore Tucker
Catharine and Rob Williams
Paul and Janine Witte

MATCHING GIFT PROGRAMS
Amazon Smile Foundation
America’s Charities
Amgen Foundation Matching Gift Program
AT&T United Way Employee Giving Campaign
Bank of America Employee Giving Campaign
Benevity Community Impact Fund
Give with Liberty Campaign
IBM Employee Services Center
JP Morgan Chase Employee Giving
Merck Partnership for Giving
Nvidia Employee Giving Program
Pledgeling Foundation
United Way California Capital Region
United Way of the Bay Area
YourCause, LLC

Thank you
TO OUR MANY IN-KIND DONORS WHO ARE TOO NUMEROUS TO MENTION.

We apologize in advance for any errors or omissions in our Donor List despite our best efforts to be as accurate as possible. Please email editor@hepb.org or call (215) 489-4900 so that we can print corrections in our next newsletter. Thank you for understanding.
YEAR IN REVIEW + FINANCIAL INFORMATION

COMBINED HEPATITIS B FOUNDATION
& BARUCH S. BLUMBERG INSTITUTE
FOR THE FISCAL YEAR ENDED JUNE 30, 2018

* The financial information presented above does not include the activity from Hepatitis B Foundation's ownership of the net assets of the Pennsylvania Biotechnology Center. At June 30, 2018, this interest was valued at, based on the equity method of accounting, approximately $4,959,000 per the audited Statement of Financial Position of the Hepatitis B Foundation.

** The financial information presented above excludes unrealized investment related activities.

*** Excludes in-kind donations

**** Baruch S. Blumberg Institute is the research institute established by the Hepatitis B Foundation in 2004.

The financial information in this report was prepared by management and presented in condensed form from the financial statements of the Hepatitis B Foundation and the Baruch S. Blumberg Institute audited by EisnerAmper, LLP for the year ended June 30, 2018.

A copy of each financial statement is available upon request.
The Hepatitis B Foundation and its Baruch S. Blumberg Institute are the nation’s leading nonprofit research and disease advocacy organizations dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. The Hepatitis B Foundation was founded in 1991, and established the Baruch S. Blumberg Institute in 2003 to fulfill its research mission.

HBF BOARD OF DIRECTORS
Chairman
Joel Rosen, Esq.
President
Timothy M. Block, PhD
Vice President
Catharine Williams, MGA
Treasurer
Joseph Hediger
Secretary
Wayne Yetter
Stanley Broadbent, MD
Carol Brosgart, MD
Nathaniel Brown, MD
Alan Brownstein, MPH
Loren Danzis, Esq.
Craig Esterly
Anthony Ford-Hutchinson, PhD
David Gruber, CPA
Raman Kapur, MBA
Thomas Shenk, PhD
Walter Tsou, MD
Su Wang, MD, MPH
Medical and Scientific Advisors
Harvey Alter, MD
Timothy M. Block, PhD
Nathaniel Brown, MD
Francis Chisari, DPhil
Raymond Dwek, DPhil, FRS
Anthony Ford-Hutchinson, PhD
Lawrence Friedman, MD
Don Ganiere, MD
Robert Gish, MD
Hie-Won L. Hann, MD
Stephen Locarnini, MD, PhD
Anna Lok, MD
William Mason, PhD
Brian McMahon, MD
Edith Mitchell, MD
Robert Perillo, MB, BChB
Raymond Sepulveda, MD
Brian Smorodin, MD
Matthew Todd, PhD
Board Members Emeritus
Joan M. Block, RN, BSN
Janine Witte

In Memoriam:
Baruch S. Blumberg, MD, DPhil
Nobel Laureate
W. Thomas London, MD
Bud Tennant, DVM
Medical Director
Robert Gish, MD
Special Advisors
Bob Bowman, PhD
Gang Chen, MD, PhD
Eddie Cheung, MD
Nadine Shimma
STAFF
President
Timothy M. Block, PhD
Executive Vice President/Chief Operating Officer
Louis P. Kassa, MBA, MPA
Senior Vice President
Chari Cohen, DrPH, MPH
Vice President, Research
Ju-Tao Guo, MD
Vice President, Institutional Advancement
Jean Holmes, MBA
Outreach and Public Health
Catherine Freeman, MPH
Michaela Jackson, MS
Maureen Karrschke
Kate Moras, MPH
Sierra Pelletch, CHES
Rhea Racho, MPH
Institutional Advancement
Jenny Kinbel
Susanna McEvian
Megan Pierce
Finance and Operations
Deborah Blough
Chris Cheshire
Nicole Grasso
Mark Hansen
Konrad Krosner
Judith Marchand
Patti McAlloon, MBA
Diana Miller
Loretta Molle
Ray Savage

BARUCH S. BLUMBERG INSTITUTE BOARD OF DIRECTORS & OFFICERS
Chairman
Wayne Yetter
President
Timothy M. Block, PhD
Treasurer
Joseph Hediger
Secretary
Louis P. Kassa, MPA (non-voting)
Loren Danzis, Esq.
Stanley Broadbent, MD
Thomas Shenk, PhD
Michael Sofia, PhD (non-voting)

HEPATITIS B FOUNDATION AND BARUCH S. BLUMBERG INSTITUTE FACULTY
Timothy M. Block, PhD
Jinhong Chang, MD, PhD
Jason Clement, PhD
Chari Cohen, DrPH, MPH
Yann Ming Du, PhD
Catherine Freeman, MPH
Ju-Tao Guo, MD
Xuanmiao Jiao, PhD
John Kulp, PhD
Patrick Lam, PhD
Zhipeng Li, PhD
Bruce Maryanoff, PhD
Sung Park, PhD
Richard Pestell, MBA, MD, PhD
Aeijaz Sayeed, PhD
Kunwar Shailubhai, PhD, MBA
Ying-Hsiu Su, PhD
Roshan Thapa, MD
Matthew Todd, PhD
Tianlin Zhou, MD, PhD, MPH
Teaching & Lab Faculty
Sahithi Pamarthy, PhD
Darrin Swartz, PhD
Wei Xie, PhD
Fanny Zhang, PhD

On-site Adjunct Faculty
Dennis Gross, MBA, PhD
Nikhil Heble, JD, PharmD
David Horn, MD
William Kinney, PhD
Cynthia Maryanoff, PhD
Raj Patil, PhD
Patrick Romano, PhD
Michael Sofia, PhD

Off-site Adjunct Faculty
Gang Chen, MD, PhD
Andrea Duconati, PhD
Doan Dao, MD, PhD
Richard Davidson, PhD
Alison Evans, ScD
Nicholas Meanwell, PhD
Chris Moore, PhD

Join Our Global Conversation
/hhepbfoundation    @hepbfoundation    @hepbfoundation
/hepbfoundation    hepb.org/blog    @hepbfoundation

3805 Old Easton Road, Doylestown, PA 18902
Phone: (215) 489-4900  Fax: (215) 489-4920  Email: info@hepb.org
Visit www.hepb.org and www.blumberginstitute.org